GSK Satisfied With Q2 Performance As Europe Returns to Growth
GSK recorded gains in Europe and the US in Q2 as it ramped up preparations for the launch of its consumer health joint venture with Pfizer.
You may also be interested in...
GSK and Pfizer must find a buyer for the global rights to the ThermaCare pain relief brand to receive European Commission approval for their proposed joint venture.
Sales to Crown Labs didn't breach GSK's attention when it reported its Q1 results, with its consumer health discussion limited to general figures on regions and product categories. Pfizer offered even less about its consumer health operations and plans with its Q1 report.For Crown Labs, landing North American rights to Keri brand marks another step toward offering comprehensive skin care selection.
Firm's Hindustan Unilever division will merge with s GSK Consumer Healthcare India which has had total sales around €550m so far in 2018, primarily through the Horlicks and Boost brands and with nearly 90% of the revenues in India. Also will acquire 82% stake in GSK Bangladesh and other GSK commercial operations and assets outside India, paying €3.3bn in combination of cash and shares in Hindustan Unilever.